Aqueous suspension comprising fenofibrate
6 claims: 6 independent, 0 dependent
- 1Aqueous suspension containing micronized fenofibrate in suspension, hydroxypropylmethylcellulose and a surfactant, characterized in that the fenofibrate/hydroxypropylmethylcellulose mass ratio is between 5/1 and 15/1. Suspension aqueuse contenant du fénofibrate micronisé en suspension, de l'hydroxypropylméthylcellulose et un tensioactif, caractérisée en ce que le rapport massique fénofibrate/hydroxypropylméthylcellulose est compris entre 5/1 et 15/1. Wässrige Suspension, die suspendiertes mikronisiertes Fenofibrat, Hydroxypropylmethylcellulose und ein Tensid enthält, dadurch gekennzeichnet, dass das Massenverhältnis Fenofibrat/Hydroxypropylmethylcellulose zwischen 5/1 und 15/1 einschließlich liegt.
- 2Suspension according to Claim 1, characterized in that the hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 18 mPa.s(cP), preferably of between 2.4 and 3.6 mPa. s (cP) . Suspension nach Anspruch 1, dadurch gekennzeichnet, dass die Hydroxypropylmethylcellulose eine scheinbare Viskosität zwischen 2,4 und 18 mPa·s (cP) einschließlich, vorzugsweise zwischen 2,4 und 3,6 mPa·s (cP) einschließlich aufweist. Suspension selon la revendication 1, caractérisé en ce que l'hydroxypropylméthylcellulose a une viscosité apparente comprise entre 2,4 et 18 mPa.s (cP), de préférence comprise entre 2,4 et 3,6 mPa.s (cP).
- 3Suspension according to either of the preceding claims, characterized in that the surfactant is chosen from the group made up of polysorbate® 80, Montane® 20 and sodium lauryl sulphate. Suspension nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, dass das Tensid ausgewählt ist aus der Gruppe, die aus Polysorbat® 80, Montane® 20 und Natriumlaurylsulfat gebildet ist. Suspension selon l'une quelconque des revendications précédentes, caractérisée en ce que le tensioactif est choisi dans le groupe formé par le polysorbate® 80, le Montane® 20 et le laurylsulfate de sodium.
- 4Suspension according to any one of the preceding claims, characterized in that the surfactant represents between 1 and 10%, preferably between 3 and 5%, by weight relative to the weight of the fenofibrate. Suspension nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, dass das Tensid zwischen 1 und 10 Gew.-%, vorzugsweise zwischen 3 und 5 Gew.-%, bezogen auf das Gewicht des Fenofibrats, ausmacht. Suspension selon l'une quelconque des revendications précédentes, caractérisée en ce que le tensioactif représente entre 1 et 10 %, de préférence entre 3 et 5 % en poids par rapport au poids du fénofibrate.
- 5Suspension according to any one of the preceding claims, characterized in that the mean size of the fenofibrate particles is less than 15 µm, preferably less than 8 µm. Suspension nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, dass die mittlere Größe der Fenofibrat-Teilchen unter 15 µm, vorzugsweise unter 8 µm liegt. Suspension selon l'une quelconque des revendications précédentes, caractérisée en ce que la taille moyenne des particules de fénofibrate est inférieure à 15 µm, de préférence inférieure à 8 µm.
- 6Use of the suspension according to any one of the preceding claims, for the preparation of granules of fenofibrate by spraying the said suspension onto neutral microgranules. Utilisation de la suspension selon l'une quelconque des revendications précédentes, pour la préparation de granules de fénofibrate par pulvérisation de ladite suspension sur des microgranules neutres. Verwendung der Suspension nach irgendeinem der vorangehenden Ansprüche für die Herstellung von Fenofibrat-Körnchen zur Zerstäubung der Suspension auf neutralen Mikroteilchen.
Independent claims6
107 paragraphs, as filed
The present invention relates to a novel aqueous suspension containing fenofibrate.
Fenofibrate is recommended in the treatment of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia endogenous adult. A treatment of 300 to 400 mg of fenofibrate per day enables a 20 to 25% of cholesterol and 40 to 50% triglycerides.
Plasma major metabolite of fenofibrate is fenofibric acid. The plasma half-life of elimination of the acid fenofibric is of the order of 20 hours. Its maximum plasma concentration is reached on average five hours after ingestion of the drug. The average plasma concentration is of the order of 15 micrograms / ml for a dose of 300 mg of fenofibrate per day. This level is stable throughout treatment.
Fenofibrate is an active principle sparingly soluble in water in the absorption level of the digestive tract is limited. An increase in its solubility or in its rate of solubilization leads to better digestive absorption.
Various approaches have been explored to increase the rate of solubilization of fenofibrate: micronization of the active principle, addition of a surfactant, and comicronization of fenofibrate with a surfactant.
The patent <patcit id="pcit0001" dnum="EP256933A"><text>EP 256 933</text></patcit> describes fenofibrate granules in which the fenofibrate is micronized in order to increase its bioavailability. The crystalline fenofibrate microparticles are of size less than 50 microns. The binder used is polyvinylpyrrolidone. The document suggests other types of binder, such as methacrylic polymers, cellulose derivatives, and polyethylene glycols. The granules described in the examples of<patcit id="pcit0002" dnum="EP256933A"><text>EP 256 933</text></patcit> are obtained by a method using organic solvents.
The patent <patcit id="pcit0003" dnum="EP330532A"><text>EP 330 532</text></patcit> proposes improving the bioavailability of fenofibrate in comicronizing with a surfactant such as sodium lauryl sulphate. The comicronizate is then granulated by wet granulation in order to improve the flow capacities of the powder and to facilitate the transformation into gelatin capsules. This comicronization allows a significant increase in the bioavailability compared to the use of fenofibrate described in<patcit id="pcit0004" dnum="EP256933A"><text>EP 256 933</text></patcit>. The granules described in<patcit id="pcit0005" dnum="EP330532A"><text>EP 330 532</text></patcit> contain polyvinylpyrrolidone as a binder.
This patent teaches that the comicronization of fenofibrate with a solid surfactant significantly improves the bioavailability of the fenofibrate compared to the use of a surfactant, of micronization or of the combination of a surfactant and micronized fenofibrate.
The <patcit id="pcit0006" dnum="WO9831361A"><text>WO 98/31361 patent</text></patcit> proposes improving the bioavailability of the fenofibrate by attaching to a hydrodispersible inert support micronized fenofibrate, a hydrophilic polymer and optionally a surfactant. The hydrophilic polymer, identified as polyvinylpyrrolidone, represents at least 20% by weight of the composition described above.
This method allows to increase the speed of dissolution of the fenofibrate, and also its bioavailability. However, the preparation method according to that patent is not entirely satisfactory since it requires the implementation of a considerable amount of PVP and of the other excipients. The example presented in that patent application refers to a composition containing only 17.7% of fenofibrate expressed as a mass ratio. This low mass ratio for fenofibrate leads to a final form very large hence a difficulty in administering the desired dose of fenofibrate, or the administration of two tablets.
It has been discovered in the context of the present invention that the incorporation of a cellulose derivative used as binder and solubilization adjuvant in a composition containing micronized fenofibrate and a surfactant makes it possible to obtain a bioavailability superior to a composition containing a co -micronisat of fenofibrate and surfactant.
The present invention therefore relates to an aqueous suspension containing micronized fenofibrate in suspension, hydroxypropylmethylcellulose and a surfactant, characterized in that the weight ratio fenofibrate / hydroxypropylmethylcellulose is between 5/1 and 15/1.
The composition of the invention is advantageously provided as gelatin capsules containing powder or granules, preferably in the form of granules. These granules may in particular be prepared by assembly on neutral microgranules, by spraying an aqueous suspension containing the surfactant, the solubilized binding cellulose derivative and the micronized fenofibrate in suspension, or by wet granulation of powder, according to which the constituents, including in particular the micronized fenofibrate, the surfactant and the cellulose are granulated by wet granulation derivative using an aqueous wetting solution, dried and calibrated.
The pharmaceutical composition according to the present invention has a high proportion of fenofibrate, it may therefore be provided in a formulation size less than the formulations of the prior art, which makes this composition according to the invention easy to administer.
The amount of fenofibrate is greater than or equal to 60% by weight, preferably greater than or equal to 70% by weight, more preferably greater than or equal to 75% by weight, based on the weight of the composition.
In the context of the present invention, the fenofibrate is not co-micronized with a surfactant. On the contrary, it is micronized alone and then combined with a surfactant and with the binding cellulose derivative, solubilization adjuvant.
The surfactant is chosen from surfactants which are solid or liquid at room temperature, for example sodium lauryl sulphate, polysorbate 80 or Montane<sup>®</sup> 20, preferably sodium lauryl sulfate.
The surfactant represents between 1 to 10%, preferably between 3 and 5% by weight relative to the weight of fenofibrate.
The binding cellulose derivative represents between 2 and 15%, preferably between 5 and 12% by weight of the composition.
hydroxypropylmethylcellulose is preferably chosen whose apparent viscosity is between 2.4 and 18 cP, and even more preferably between 2.4 and 3.6 cP, such as Pharmacoat 603®.
The mean size of the fenofibrate particles is less than 15 .mu.m, preferably 10 .mu.m, more preferably less than 8 .mu.m.
The composition of the invention may further contain at least one excipient such as diluents such as lactose, antifoaming agents such as Diméthicone® and Siméthicone®, lubricants such as talc.
The pharmaceutical composition of the invention advantageously consists of granules in an amount equivalent to a dose of fenofibrate of between 50 and 300 mg, preferably equal to 200 mg.
The present invention also relates to a powder preparation process or granules whose composition is described above. This method uses no organic solvent.
In a first variant, the granules are prepared by assembly on neutral microgranules.
The neutral microgranules have a particle size between 200 and 1000 microns, preferably between 400 and 600 microns.
The mounting is effected by coating turbine, in a perforated pan or in a fluidized airbed, preferably in a fluidized air bed.
The assembly on neutral microgranules is carried out by spraying an aqueous suspension containing the surfactant, the solubilized binding cellulose derivative and the micronized fenofibrate in suspension.
In a second variant, the granules are obtained by powder wet granulation. The granulation allows to densify the powders to improve their flow properties. It also allows better preservation of the homogeneity, by avoiding demixing of the various constituents.
The micronized fenofibrate, the surfactant, the cellulose derivative and optionally other excipients are mixed, granulated, dried and then calibrated. The wetting solution may be water or an aqueous solution containing the cellulose derivative binder and / or surfactant.
According to a particular mode of implementation, fenofibrate and the other excipients are mixed in a planetary mixer. The dampening solution is fed directly into the mixture. The moistened mass obtained is granulated with an oscillating granulator, and then dried in an oven. The granules are obtained after passage over oscillating calibrator.
The <figref idrefs="f0001">figure 1</figref> represents the in vivo release profile of the formulation of example 1C and of a formulation of the prior art in fasting subjects.
The <figref idrefs="f0002">2</figref> represents the in vivo release profile of the formulation of example 1C and of a formulation of the prior art in individuals who have just eaten.
The <figref idrefs="f0003">3</figref> represents the in vivo release profile of the formulation of example 2B and of a formulation of the prior art in fasting subjects.
The <figref idrefs="f0004">4</figref> represents the in vivo release profile of the formulation of comparative example 3 and of a formulation of the prior art in individuals who have just eaten.
The invention is illustrated without limitation by the following examples.
<u>example 1</u> : Granules
1A) <u>Microgranules (XFEN 1735)</u>
The microgranules are obtained by spraying an aqueous suspension onto neutral cores. The composition is presented in the following table:<tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="56mm" /><thead valign="top"><row><entry align="center"><b>Formula</b></entry><entry align="center"><b>Quantity (Percentage Massic)</b></entry></row></thead><tbody><row><entry>micronized fenofibrate</entry><entry align="center">64.5</entry></row><row><entry>Micro neutral granules</entry><entry align="center">21</entry></row><row><entry>HPMC (Pharmacoat 603<sup>®</sup> )</entry><entry align="center">11.2</entry></row><row><entry>polysorbate<sup>®</sup> 80</entry><entry align="center">3.3</entry></row><row><entry>Content fenofibrate</entry><entry align="center">645 mg / g</entry></row></tbody></tgroup></table></tables>
The in vitro dissolution is determined according to a method in continuous flow cells with a flow rate of 8 ml / min of sodium lauryl sulfate at 0.1 N. The percentages of dissolved product as a function of time in comparison with a formulation of the art anterior Lipanthyl 200 million, are presented in the following table. <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="12mm" /><tbody><row><entry>Time (min)</entry><entry align="center">15</entry><entry align="center">thirty</entry></row><row><entry>Example 1A (% dissolved)</entry><entry align="center">73</entry><entry align="center">95</entry></row><row><entry>Lipanthyl 200M (% dissolved)</entry><entry align="center">47.3</entry><entry align="center">64.7</entry></row></tbody></tgroup></table></tables>
1A formulation has a faster dissolution than Lipanthyl 200M.
<u>1B) Microgranules (X FEN 1935)</u>
The mean size of the fenofibrate particles is equal to 6.9 ± 0.7 microns.
The microgranules are obtained by spraying an aqueous suspension onto neutral cores. The suspension contains micronized fenofibrate, sodium lauryl sulfate and HPMC.
The assembly is carried out in a fluidized air bed Hüttlin (rotoprocess).
The formula obtained is shown below.<tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="59mm" /><thead valign="top"><row><entry align="center"><b>FORMULA</b></entry><entry align="center"><b>QUANTITY (percentage by weight)</b></entry></row></thead><tbody><row><entry>micronized fenofibrate</entry><entry align="center">65.2</entry></row><row><entry>neutral microgranules</entry><entry align="center">20.1</entry></row><row><entry>HPMC (Pharmacoat 603®)</entry><entry align="center">11.4</entry></row><row><entry>sodium lauryl sulfate</entry><entry align="center">3.3</entry></row><row><entry>Content fenofibrate</entry><entry align="center">652 mg / g</entry></row></tbody></tgroup></table></tables>
The size of the neutral microgranules is between 400 and 600 .mu.m.
<u>1C) Capsules of Microgranules (Y FEN 001)</u>
microgranules are prepared following composition: <tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="59mm" /><thead valign="top"><row><entry align="center"><b>RAW MATERIALS</b></entry><entry align="center"><b>QUANTITY (percentage by weight)</b></entry></row></thead><tbody><row><entry>micronized fenofibrate</entry><entry align="center">67.1</entry></row><row><entry>neutral microgranules</entry><entry align="center">17.2</entry></row><row><entry>Pharmacoat 603® (HPMC)</entry><entry align="center">11.7</entry></row><row><entry>sodium lauryl sulfate</entry><entry align="center">3.3</entry></row><row><entry>Dimethicone emulsion 35%</entry><entry align="center">0.2</entry></row><row><entry>Talc</entry><entry align="center">0.5</entry></row><row><entry>Content fenofibrate</entry><entry align="center">671 mg / g</entry></row></tbody></tgroup></table></tables>
According to the method described in paragraph 1A).
The microgranules obtained are distributed into size 1 gelatin capsules, each containing 200 mg of fenofibrate.
The in vitro dissolution is determined according to a cell method continuous flow with a flow rate of 8ml / min of sodium lauryl sulfate at 0.1 N. The comparative results with a formulation of the prior art, Lipanthyl 200, are shown in following table.<tables id="tabl0005" num="0005"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="12mm" /><tbody><row><entry>Time (min)</entry><entry align="center">15</entry><entry align="center">thirty</entry></row><row><entry>Example 1C (% dissolved)</entry><entry align="center">76</entry><entry align="center">100</entry></row><row><entry>Lipanthyl 200M (% dissolved)</entry><entry align="center">47.3</entry><entry align="center">64.7</entry></row></tbody></tgroup></table></tables>
1C formulation has a faster dissolution than Lipanthyl 200M.
The capsules are conserved for 6 months at 40 ° C / 75% relative humidity. The granules are stable under these accelerated storage conditions. In vitro dissolution tests (in continuous flow cells with a flow rate of 8 ml / min of sodium lauryl sulfate at 0.1 N) were carried out. Product percentages of dissolved versus time for gelatin capsules conserved for 1, 3 and 6 months are shown in the following table.<tables id="tabl0006" num="0006"><table frame="all"><tgroup cols="4" rowsep="0"><colspec colnum="1" colname="col1" colwidth="40mm" /><colspec colnum="2" colname="col2" colwidth="42mm" /><colspec colnum="3" colname="col3" colwidth="42mm" /><colspec colnum="4" colname="col4" colwidth="43mm" /><thead valign="top"><row><entry morerows="1" align="center" valign="middle"><b>Dissolution time (min)</b></entry><entry namest="col2" nameend="col4" align="center"><b>Shelf life</b></entry></row><row><entry align="center"><b>1 month (% dissolved product)</b></entry><entry align="center"><b>3 months (% dissolved product)</b></entry><entry align="center"><b>6 months (% dissolved product)</b></entry></row></thead><tbody><row><entry align="center">5</entry><entry align="center">25.1</entry><entry align="center">23.0</entry><entry align="center">20.1</entry></row><row><entry align="center">15</entry><entry align="center">71.8</entry><entry align="center">65.6</entry><entry align="center">66.5</entry></row><row><entry align="center">25</entry><entry align="center">95.7</entry><entry align="center">88.7</entry><entry align="center">91.0</entry></row><row><entry align="center">35</entry><entry align="center">104.7</entry><entry align="center">98.7</entry><entry align="center">98.2</entry></row><row><entry align="center">45</entry><entry align="center">106.4</entry><entry align="center">100.2</entry><entry align="center">99.1</entry></row><row><entry align="center">55</entry><entry align="center">106.7</entry><entry align="center">100.5</entry><entry align="center">99.5</entry></row><row><entry align="center">65</entry><entry align="center">106.8</entry><entry align="center">100.6</entry><entry align="center">99.7</entry></row></tbody></tgroup></table></tables>
The evolution of the active ingredient content during storage is presented in the following table.<tables id="tabl0007" num="0007"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="33mm" /><colspec colnum="2" colname="col2" colwidth="13mm" /><colspec colnum="3" colname="col3" colwidth="15mm" /><colspec colnum="4" colname="col4" colwidth="15mm" /><colspec colnum="5" colname="col5" colwidth="15mm" /><thead valign="top"><row><entry rowsep="0" align="center" valign="middle" /><entry namest="col2" nameend="col5" align="center"><b>Shelf life</b></entry></row><row><entry rowsep="0" valign="middle"><b>Content (mg / capsule)</b></entry><entry align="center"><b>0</b></entry><entry align="center"><b>1 month</b></entry><entry align="center"><b>3 months</b></entry><entry align="center"><b>6 months</b></entry></row></thead><tbody><row><entry valign="middle" /><entry align="center">208.6</entry><entry align="center">192.6</entry><entry align="center">190.8</entry><entry align="center">211.7</entry></row></tbody></tgroup></table></tables>
<u>pharmacokinetic study conducted in the fasted state</u>
Comparing the in vivo release profile of the capsules containing the granules YFEN 01 dosed at 200 mg of fenofibrate, for the capsules marketed under the trademark Lipanthyl 200.
This study was conducted in 9 subjects. Blood samples are taken at regular time intervals and fenofibric acid is assayed.
The results are shown in the following table and <figref idrefs="f0001">figure 1</figref>. <tables id="tabl0008" num="0008"><table frame="all"><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="57mm" /><colspec colnum="2" colname="col2" colwidth="29mm" /><colspec colnum="3" colname="col3" colwidth="23mm" /><thead valign="top"><row><entry align="center"><b>pharmacokinetics</b></entry><entry align="center"><b>Lipanthyl 200M</b></entry><entry align="center"><b>example 1C</b></entry></row></thead><tbody><row><entry align="center">AUC<sub>0-t</sub></entry><entry align="center">76</entry><entry align="center">119</entry></row><row><entry align="center">(Μg.h / ml)</entry></row><row><entry align="center" /></row><row><entry align="center">AUC<sub>inf</sub></entry><entry align="center">96</entry><entry align="center">137</entry></row><row><entry align="center">(Μg.h / ml)</entry></row><row><entry align="center" /></row><row><entry align="center">C<sub>max</sub></entry><entry align="center">2.35</entry><entry align="center">4.71</entry></row><row><entry align="center">(Ug / ml)</entry></row><row><entry align="center" /></row><row><entry align="center">T<sub>max</sub></entry><entry align="center">8.0</entry><entry align="center">5.5</entry></row><row><entry align="center">(Hours)</entry></row><row><entry align="center" /></row><row><entry align="center">Ke</entry><entry align="center">0,032</entry><entry align="center">0,028</entry></row><row><entry align="center">(1 hour)</entry></row><row><entry align="center" /></row><row><entry rowsep="0" align="center">Elim ½</entry><entry rowsep="0" align="center">26.7</entry><entry rowsep="0" align="center">24.9</entry></row><row><entry rowsep="1" align="center">(Hours)</entry><entry rowsep="1" align="center" /><entry rowsep="1" align="center" /></row><row><entry namest="col1" nameend="col3" align="justify">The following abbreviations are used in this application: C<sub>max</sub> : Maximum plasma concentration, T<sub>max</sub> : Time to reach the Cmax, Elim<sub>½</sub>: Plasma half-life, AUC<sub>0-t</sub> : Area under the curve from 0 to t, AUC<sub>0-∞</sub> : Area under the curve from 0 to ∞, Ke: elimination rate constant.</entry></row></tbody></tgroup></table></tables>
The results obtained for Lipanthyl 200 M and for the product of example 1C are represented on the <figref idrefs="f0001">figure 1</figref> respectively by curves 1 and 2.
These results show that the composition of the present invention has a superior bioavailability to that of Lipanthyl 200 M in fasting subjects.
<u>Pharmacokinetic study conducted in subjects who have just eaten</u>
Comparing the in vivo release profile of the capsules containing the granules YFEN 01 dosed at 200 mg of fenofibrate, for the capsules marketed under the trademark Lipanthyl 200 M.
This study was conducted in 18 subjects. Blood samples are taken at regular time intervals and fenofibric acid is assayed. The results are shown in the following table and <figref idrefs="f0002">2</figref>.<tables id="tabl0009" num="0009"><table frame="all"><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="54mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><colspec colnum="3" colname="col3" colwidth="24mm" /><thead valign="top"><row><entry align="center"><b>pharmacokinetics</b></entry><entry align="center"><b>Lipanthyl 200M</b></entry><entry align="center"><b>example 1C</b></entry></row></thead><tbody><row><entry>AUC<sub>0-t</sub></entry><entry align="center">244</entry><entry align="center">257</entry></row><row><entry>(Μg.h / ml)</entry></row><row><entry>AUC<sub>inf</sub></entry><entry align="center">255</entry><entry align="center">270</entry></row><row><entry>(Μg.h / ml)</entry></row><row><entry>C<sub>max</sub></entry><entry align="center">12</entry><entry align="center">13</entry></row><row><entry>(Ug / ml)</entry></row><row><entry>T<sub>max</sub></entry><entry align="center">5.5</entry><entry align="center">5.5</entry></row><row><entry>(Hours)</entry></row><row><entry>Ke</entry><entry align="center">0.04</entry><entry align="center">0.04</entry></row><row><entry>(1 hour)</entry></row><row><entry>Elim ½</entry><entry align="center">19.6</entry><entry align="center">19.3</entry></row><row><entry>(Hours)</entry></row></tbody></tgroup></table></tables>
The results obtained for Lipanthyl 200 M and for the product of example 1C are represented on the <figref idrefs="f0002">2</figref> respectively by curves 1 and 2.
These results show that the composition of the present invention is bioequivalent to that of Lipanthyl 200 in the subject that comes to eat.
<u>example 2</u> : Powder
2A) <u>Pellets (X FEN 1992)</u>
Granules were prepared with the following composition <tables id="tabl0010" num="0010"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="48mm" /><thead valign="top"><row><entry align="center"><b>FORMULA</b></entry><entry align="center"><b>MASS PERCENTAGE</b></entry></row></thead><tbody><row><entry>micronized fenofibrate</entry><entry align="center">71</entry></row><row><entry>Lactose</entry><entry align="center">21.5</entry></row><row><entry>HPMC (Pharmacoat 603<sup>®</sup>)</entry><entry align="center">5</entry></row><row><entry>sodium lauryl sulfate</entry><entry align="center">2.5</entry></row></tbody></tgroup></table></tables>
The micronized fenofibrate, the HPMC and the lactose are mixed using a planetary mixer. This mixture is granulated in the presence of a sodium lauryl sulfate solution.
The flow time of the granules is 7 s. The ability to compaction and particle size distribution are presented in the following tables. These measurements were performed according to the standards of the European Pharmacopoeia.<tables id="tabl0011" num="0011"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="30mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><thead valign="top"><row><entry namest="col1" nameend="col2" align="center"><b>Ability to compaction (X FEN 1992)</b></entry></row></thead><tbody><row><entry align="center">V0</entry><entry align="center">204 ml</entry></row><row><entry align="center">V10</entry><entry align="center">186 ml</entry></row><row><entry align="center">V500</entry><entry align="center">168 ml</entry></row><row><entry align="center">V1250</entry><entry align="center">164 ml</entry></row><row><entry align="center">V10-V500</entry><entry align="center">22 ml</entry></row></tbody></tgroup></table></tables><tables id="tabl0012" num="0012"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="58mm" /><colspec colnum="2" colname="col2" colwidth="36mm" /><thead valign="top"><row><entry namest="col1" nameend="col2" align="center"><b>Particle size distribution (X FEN 1992)</b></entry></row><row><entry align="center"><b>sieve mesh width (mm)</b></entry><entry align="center"><b>% Mass refusal</b></entry></row></thead><tbody><row><entry align="center">0.6</entry><entry align="center">8</entry></row><row><entry align="center">0.5</entry><entry align="center">9</entry></row><row><entry align="center">0,355</entry><entry align="center">12</entry></row><row><entry align="center">0.2</entry><entry align="center">thirty</entry></row><row><entry align="center">0.1</entry><entry align="center">23</entry></row><row><entry align="center">0</entry><entry align="center">18</entry></row></tbody></tgroup></table></tables>
<u>2B) Capsules granules (Y FEN 002)</u>
• Preparation
The micronized fenofibrate is mixed in a PMA mixer (Niro Fielder) with lactose and HPMC, and then wetted with an aqueous solution of sodium lauryl sulfate. The mass obtained is granulated by passage over an oscillating granulator, dried and then calibrated on a sieve of 1.25 mm mesh width.
The granules are then packaged in capsules of size 1 dosed at 200 mg of fenofibrate.
Are obtained following composition pellets.<tables id="tabl0013" num="0013"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="48mm" /><thead valign="top"><row><entry align="center"><b>FORMULA</b></entry><entry align="center"><b>MASS PERCENTAGE</b></entry></row></thead><tbody><row><entry>micronized fenofibrate</entry><entry align="center">70</entry></row><row><entry>Lactose</entry><entry align="center">21.5</entry></row><row><entry>Pharmacoat 603® (HPMC)</entry><entry align="center">5</entry></row><row><entry>sodium lauryl sulfate</entry><entry align="center">3.5</entry></row><row><entry>Content</entry><entry align="center">700 mg / g</entry></row></tbody></tgroup></table></tables>
• Properties of granules
The flow time of the granules is 6 s. The ability to compaction and particle size distribution are presented in the following tables. These measurements were performed according to the standards of the European Pharmacopoeia.<tables id="tabl0014" num="0014"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="29mm" /><colspec colnum="2" colname="col2" colwidth="27mm" /><thead valign="top"><row><entry namest="col1" nameend="col2" align="center"><b>Ability to compaction (Y FEN 002)</b></entry></row></thead><tbody><row><entry align="center">V0</entry><entry align="center">216 ml</entry></row><row><entry align="center">V10</entry><entry align="center">200 ml</entry></row><row><entry align="center">V500</entry><entry align="center">172 ml</entry></row><row><entry align="center">V1250</entry><entry align="center">170 ml</entry></row><row><entry align="center">V10-V500</entry><entry align="center">28 ml</entry></row></tbody></tgroup></table></tables><tables id="tabl0015" num="0015"><table frame="all"><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="57mm" /><colspec colnum="2" colname="col2" colwidth="35mm" /><thead valign="top"><row><entry namest="col1" nameend="col2" align="center"><b>Particle size distribution (Y FEN 002)</b></entry></row><row><entry align="center"><b>sieve mesh width (mm)</b></entry><entry align="center"><b>% Mass refusal</b></entry></row></thead><tbody><row><entry align="center">0.6</entry><entry align="center">5</entry></row><row><entry align="center">0.5</entry><entry align="center">7</entry></row><row><entry align="center">0,355</entry><entry align="center">11</entry></row><row><entry align="center">0.2</entry><entry align="center">thirty</entry></row><row><entry align="center">0.1</entry><entry align="center">25</entry></row><row><entry align="center">0</entry><entry align="center">22</entry></row></tbody></tgroup></table></tables>
The in vitro dissolution is determined according to a method in continuous flow cells with a flow rate of 8 ml / min of sodium lauryl sulfate at 0.1 N. The comparative results with a formulation of the prior art, Lipanthyl 200 M, are given in the following table.<tables id="tabl0016" num="0016"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="12mm" /><tbody><row><entry>Time (min)</entry><entry align="center">15</entry><entry align="center">thirty</entry></row><row><entry>Example 2B (% dissolved)</entry><entry align="center">82.2</entry><entry align="center">88.5</entry></row><row><entry>Lipanthyl 200 M (% dissolved)</entry><entry align="center">47.3</entry><entry align="center">64.7</entry></row></tbody></tgroup></table></tables>
The formulation 2B shows a faster dissolution than Lipanthyl 200 M.
• Stability Testing
Capsules stored at 40 ° C / 75% relative humidity are stable for 6 months.
In vitro dissolution tests (in continuous flow cells with a flow rate of 8 ml / min of sodium lauryl sulfate at 0.1 N) were carried out. Product percentages of dissolved versus time for gelatin capsules conserved for 1, 3 and 6 months are shown in the following table.<tables id="tabl0017" num="0017"><table frame="all"><tgroup cols="4" rowsep="0"><colspec colnum="1" colname="col1" colwidth="40mm" /><colspec colnum="2" colname="col2" colwidth="42mm" /><colspec colnum="3" colname="col3" colwidth="42mm" /><colspec colnum="4" colname="col4" colwidth="43mm" /><thead valign="top"><row><entry morerows="1" align="center" valign="middle"><b>Dissolution time (min)</b></entry><entry namest="col2" nameend="col4" align="center"><b>Shelf life</b></entry></row><row><entry align="center"><b>1 month (% dissolved product)</b></entry><entry align="center"><b>3 months (% dissolved product)</b></entry><entry align="center"><b>6 months (% dissolved product)</b></entry></row></thead><tbody><row><entry align="center">5</entry><entry align="center">54.2</entry><entry align="center">52.9</entry><entry align="center">49.0</entry></row><row><entry align="center">15</entry><entry align="center">81.1</entry><entry align="center">75.8</entry><entry align="center">82.2</entry></row><row><entry align="center">25</entry><entry align="center">86.4</entry><entry align="center">79.6</entry><entry align="center">87.2</entry></row><row><entry align="center">35</entry><entry align="center">88.8</entry><entry align="center">81.6</entry><entry align="center">89.8</entry></row><row><entry align="center">45</entry><entry align="center">90.7</entry><entry align="center">82.9</entry><entry align="center">91.5</entry></row><row><entry align="center">55</entry><entry align="center">92.1</entry><entry align="center">83.9</entry><entry align="center">92.7</entry></row><row><entry align="center">65</entry><entry align="center">93.2</entry><entry align="center">84.7</entry><entry align="center">93.6</entry></row></tbody></tgroup></table></tables>
The evolution of the active ingredient content during storage is presented in the following table.<tables id="tabl0018" num="0018"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="33mm" /><colspec colnum="2" colname="col2" colwidth="13mm" /><colspec colnum="3" colname="col3" colwidth="15mm" /><colspec colnum="4" colname="col4" colwidth="15mm" /><colspec colnum="5" colname="col5" colwidth="15mm" /><thead valign="top"><row><entry rowsep="0" align="center" /><entry namest="col2" nameend="col5" align="center"><b>Shelf life</b></entry></row><row><entry rowsep="0"><b>Content (mg / capsule)</b></entry><entry align="center"><b>0</b></entry><entry align="center"><b>1 month</b></entry><entry align="center"><b>3 months</b></entry><entry align="center"><b>6 months</b></entry></row></thead><tbody><row><entry align="char" char=",">196.6</entry><entry align="char" char="," charoff="37">190.0</entry><entry align="char" char="," charoff="37">199.8</entry><entry align="char" char="," charoff="37">203.3</entry></row></tbody></tgroup></table></tables>
<u>pharmacokinetic study conducted in the fasted state</u>
Comparing the in vivo release profile of the capsules containing the granules YFEN 002 dosed at 200 mg of fenofibrate, for the capsules marketed under the trademark Lipanthyl 200 M.
This study was conducted in 9 subjects. Blood samples are taken at regular time intervals and fenofibric acid is assayed.
The results are shown in the following table and <figref idrefs="f0003">3</figref>. <tables id="tabl0019" num="0019"><table frame="all"><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="54mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><colspec colnum="3" colname="col3" colwidth="24mm" /><thead valign="top"><row><entry align="center"><b>pharmacokinetics</b></entry><entry align="center"><b>Lipanthyl 200M</b></entry><entry align="center"><b>example 2B</b></entry></row></thead><tbody><row><entry>AUC<sub>0-t</sub></entry><entry align="center">76</entry><entry align="center">70</entry></row><row><entry>(Μg.h / ml)</entry></row><row><entry>AUC<sub>inf</sub></entry><entry align="center">96</entry><entry align="center">82</entry></row><row><entry>(Μg.h / ml)</entry></row><row><entry>C<sub>max</sub></entry><entry align="center">2.35</entry><entry align="center">2.8</entry></row><row><entry>(Ug / ml)</entry></row><row><entry>T<sub>max</sub></entry><entry align="center">8.0</entry><entry align="center">5.5</entry></row><row><entry>(Hours)</entry></row><row><entry>Ke</entry><entry align="center">0, 032</entry><entry align="center">0.033</entry></row><row><entry>(1 hour)</entry></row><row><entry>Elim ½</entry><entry align="center">26.7</entry><entry align="center">23.1</entry></row><row><entry>(Hours)</entry></row></tbody></tgroup></table></tables>
The results obtained for Lipanthyl 200 M and for the product of Example 2B are shown in <figref idrefs="f0003">3</figref> respectively by curves 1 and 2.
These results show that the composition of example 2B is bioequivalent to that of Lipanthyl 200 M in the fasted state.
<u>Comparative Example 3</u> : Batch ZEF 001
This example illustrates the prior art.
It combines micronization of fenofibrate and the use of a surfactant. It differs from the present invention by the use of a mixture of excipients binder consisting of a cellulose derivative other than HPMC: Avicel PH 101 and polyvinylpyrrolidone (PVP K30).
It is prepared by extrusion-spheronization.
• Theoretical formula
<tables id="tabl0020" num="0020"><table frame="all"><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="36mm" /><colspec colnum="2" colname="col2" colwidth="39mm" /><thead valign="top"><row><entry align="center"><b>products</b></entry><entry align="center"><b>Theoretical amount (%)</b></entry></row></thead><tbody><row><entry>micronized fenofibrate</entry><entry align="center">75.08</entry></row><row><entry>Montanox 80<sup>®</sup></entry><entry align="center">4.72</entry></row><row><entry>Avicel PH 101<sup>®</sup></entry><entry align="center">5.02</entry></row><row><entry>PVP K 30<sup>®</sup></entry><entry align="center">4.12</entry></row><row><entry>Explotab<sup>®</sup></entry><entry align="center">11.06</entry></row></tbody></tgroup></table></tables>
• in vitro dissolution profile
The in vitro dissolution is determined according to a method in continuous flow cells with a flow rate of 8 ml / min of sodium lauryl sulfate at 0.1 N. The comparative results with Lipanthyl 200 M, are given in the following table.<tables id="tabl0021" num="0021"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="12mm" /><tbody><row><entry>Time (min)</entry><entry align="center">15</entry><entry align="center">thirty</entry></row><row><entry>Example 3 (% dissolved)</entry><entry align="center">24</entry><entry align="center">40</entry></row><row><entry>Lipanthyl 200 M (% dissolved)</entry><entry align="center">47.3</entry><entry align="center">64.7</entry></row></tbody></tgroup></table></tables>
The dissolution is slower than that observed for Lipanthyl 200 M.
pharmacokinetic study conducted in the fasted state
Comparing the in vivo release profile of the gelatin capsules containing the ZEF 001 granules at dosage 200 mg of fenofibrate, for the capsules marketed under the trademark Lipanthyl 200 M.
This study was conducted in 5 subjects fasting, receiving a single dose. Blood samples are taken at regular time intervals and fenofibric acid is assayed.
The results are shown in the following table and <figref idrefs="f0004">4</figref>.<tables id="tabl0022" num="0022"><table frame="all"><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="54mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><colspec colnum="3" colname="col3" colwidth="20mm" /><thead valign="top"><row><entry align="center"><b>pharmacokinetics</b></entry><entry align="center"><b>Lipanthyl 200M</b></entry><entry align="center"><b>example 3</b></entry></row></thead><tbody><row><entry>AUC<sub>0-t</sub></entry><entry align="center">92</entry><entry align="center">47</entry></row><row><entry>(Μg.h / ml)</entry></row><row><entry>AUC<sub>inf</sub></entry><entry align="center">104</entry><entry align="center">53</entry></row><row><entry>(Μg.h / ml)</entry></row><row><entry>C<sub>max</sub></entry><entry align="center">3.5</entry><entry align="center">1.7</entry></row><row><entry>(Ug / ml)</entry></row><row><entry>T<sub>max</sub></entry><entry align="center">5.6</entry><entry align="center">4.6</entry></row><row><entry>(Hours)</entry></row><row><entry>Ke</entry><entry align="center">0.04</entry><entry align="center">0,038</entry></row><row><entry>(1 hour)</entry></row><row><entry>Elim ½</entry><entry align="center">18.9</entry><entry align="center">20.3</entry></row><row><entry>(Hours)</entry></row></tbody></tgroup></table></tables>
The results obtained for Lipanthyl 200 M and for the product of Example 3 are shown in <figref idrefs="f0004">4</figref> respectively by curves 1 and 2.
These results show the greater bioavailability of Lipanthyl 200 million compared with this formulation based on the prior art.
Example 3 shows that combining the knowledge of the prior art (namely micronization or use of surfactants) does not allow to obtain rapid dissolution of fenofibrate. This results in low bioavailability compared to Lipanthyl 200 M.
The compositions produced according to the present invention show more rapid dissolution than the formula of the prior art and improved bioavailability.
4 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4
Every citation, both ways
| Document | Relation | Office |
|---|---|---|
| EP0514967A | Cites | European Patent Office (EPO) |
| EP0519144A | Cites | European Patent Office (EPO) |
| WO9800116A | Cites | World Intellectual Property Organization (WIPO) |
| WO9831361A | Cites | World Intellectual Property Organization (WIPO) |
133 members in 38 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 9908923 | France | A | |
| 9908923 | France | A | |
| 9908923 | France | – | |
| 00949677 | European Patent Office (EPO) | A | |
| 00949677 | European Patent Office (EPO) | A | |
| 00949677 | – | – | – |
| 9908923 | – | – | – |
| EP20000949677 | – | – | – |
| FR19990008923 | – | – | – |
Members133
| Document | Office | Kind | |
|---|---|---|---|
| FR2795961A1 | France | A1 | |
| CA2377909A1 | Canada | A1 | |
| WO0103693A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU6296000A | Australia | A | |
| NO20020014D0 | Norway | D0 | |
| IS6218A | Iceland | A | |
| NO20020014L | Norway | L | |
| BR0012335A | Brazil | A | |
| KR20020025188A | Republic of Korea | A | |
| EP1194140A1 | European Patent Office (EPO) | A1 | |
| CZ20022A3 | Czechia | A3 | |
| MXPA02000324A | Mexico | A | |
| TR200200008T2 | Türkiye | T2 | |
| EA200200147A1 | Eurasian Patent Organization (EAPO) | A1 | |
| SK152002A3 | Slovakia | A3 | |
| CN1360499A | China | A | |
| ZA200200169B | South Africa | B | |
| IL147499D0 | Israel | D0 | |
| BG106280A | Bulgaria | A | |
| HU0202338A2 | Hungary | A2 | |
| HUP0202338A2 | Hungary | A2 | |
| HK1044894A1 | Hong Kong, China | A1 | |
| JP2003504331A | Japan | A | |
| EE200200011A | Estonia | A | |
| HU0202338A3 | Hungary | A3 | |
| HUP0202338A3 | Hungary | A3 | |
| HRP20020111A2 | Croatia | A2 | |
| PL352307A1 | Poland | A1 | |
| NZ516416A | New Zealand | A | |
| EA004294B1 | Eurasian Patent Organization (EAPO) | B1 | |
| FR2795961B1 | France | B1 | |
| US2004137055A1 | United States of America | A1 | |
| GEP20043287B | Georgia | B | |
| YU93201A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| EP1194140B1 | European Patent Office (EPO) | B1 | |
| AU2004277757A1 | Australia | A1 | |
| CA2540235A1 | Canada | A1 | |
| WO2005032526A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AT291912T | Austria | T | |
| ATE291912T1 | Austria | T1 | |
| EP1523983A1 | European Patent Office (EPO) | A1 | |
| DE60019120D1 | Germany | D1 | |
| UA72925C2 | Ukraine | C2 | |
| CN1204885C | China | C | |
| HK1044894B | Hong Kong, China | B | |
| SI1194140T1 | Slovenia | T1 | |
| DK1194140T3 | Denmark | T3 | |
| AU782282B2 | Australia | B2 | |
| ES2235919T3 | Spain | T3 | |
| PT1194140E | Portugal | E | |
| EP1574214A1 | European Patent Office (EPO) | A1 | |
| CN1682707A | China | A | |
| HK1074588A1 | Hong Kong, China | A1 | |
| HRP20020111B1 | Croatia | B1 | |
| DE60019120T2 | Germany | T2 | |
| HK1080391A1 | Hong Kong, China | A1 | |
| NO20061960L | Norway | L | |
| MXPA06003656A | Mexico | A | |
| EP1667666A1 | European Patent Office (EPO) | A1 | |
| KR20060073549A | Republic of Korea | A | |
| HK1084895A1 | Hong Kong, China | A1 | |
| IL174660D0 | Israel | D0 | |
| US7101574B1 | United States of America | B1 | |
| EP1574214B1 | European Patent Office (EPO) | B1 | |
| AT341320T | Austria | T | |
| ATE341320T1 | Austria | T1 | |
| CN1863518A | China | A | |
| IS2157B | Iceland | B | |
| DE60031184D1 | Germany | D1 | |
| BRPI0414860A | Brazil | A | |
| KR20060123728A | Republic of Korea | A | |
| SI1574214T1 | Slovenia | T1 | |
| DK1574214T3 | Denmark | T3 | |
| PT1574214E | Portugal | E | |
| IL147499A | Israel | A | |
| KR20070026716A | Republic of Korea | A | |
| JP2007507486A | Japan | A | |
| US2007071812A1 | United States of America | A1 | |
| ES2271924T3 | Spain | T3 | |
| ZA200603504B | South Africa | B | |
| DE60031184T2 | Germany | T2 | |
| KR100766644B1 | Republic of Korea | B1 | |
| EE04995B1 | Estonia | B1 | |
| EP1523983B1This record | European Patent Office (EPO) | B1 | |
| AT399006T | Austria | T | |
| ATE399006T1 | Austria | T1 | |
| DE60039313D1 | Germany | D1 | |
| PT1523983E | Portugal | E | |
| US2008248101A1 | United States of America | A1 | |
| DK1523983T3 | Denmark | T3 | |
| BG65504B1 | Bulgaria | B1 | |
| ME01361B | Montenegro | B | |
| RS50035B | Serbia | B | |
| EP2000133A2 | European Patent Office (EPO) | A2 | |
| ES2309438T3 | Spain | T3 | |
| CZ300094B6 | Czechia | B6 | |
| EP1667666B1 | European Patent Office (EPO) | B1 | |
| EP2000133A3 | European Patent Office (EPO) | A3 | |
| AT428408T | Austria | T | |
| ATE428408T1 | Austria | T1 |
84 legal events, as 14 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Patent expired because of reaching the maximum lifetime of a patentExpiredMK | MK | NL | |
| Expiry of rightR071 | R071 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | BE | |
| Lapse because of not paying annual feesLapsedMM01 | MM01 | AT | |
| Ep patent has lapsedLapsedEUG | EUG | SE | |
| Patent ceasedCeasedPL | PL | CH | |
| Ep patent lapsedLapsedEBP | EBP | DK | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Lien (pledge) cancelledRG | RG | FR | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Lien (pledge) cancelledRG | RG | FR | |
| Lien (pledge) constitutedGC | GC | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Lien (pledge) constitutedGC | GC | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Translation of granted ep patentGrantedTRGR | TRGR | SE | |
| Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A | SC4A | PT | |
| Standard patents granted in hong kongGrantedGR | GR | HK | |
| European patents granted designating irelandGrantedLANGUAGE OF EP DOCUMENT: FRENCHFG4D | FG4D | IE | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| New agentNV | NV | CH | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| European patent grantedGrantedNOT ENGLISHFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Title (correction)AQUEOUS SUSPENSION COMPRISING FENOFIBRATERTI1 | RTI1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designation fees paidAKX | AKX | EP | |
| Extension fees paidAXX | AXX | EP | |
| Extension fees paidAXX | AXX | EP | |
| Extension fees paidAXX | AXX | EP | |
| Extension fees paidAXX | AXX | EP | |
| Extension fees paidAXX | AXX | EP | |
| Extension fees paidAXX | AXX | EP | |
| Requests to designate patent in hong kongDE | DE | HK | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Request for examination filed17P | 17P | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1523983
- Publication, DOCDB
- 1523983
- Publication, EPODOC
- EP1523983
- Application
- 4027226
- Application, DOCDB
- 04027226
- Application, EPODOC
- EP20040027226
Titles3
- German
- Wässrige Suspension enthaltend Fenofibrat
- English
- Aqueous suspension comprising fenofibrate
- French
- Suspension aqueuse contenant du fénofibrate
Classification
- CPC, 10
- A61K31/216
- A61K9/1617
- A61K9/1623
- A61K9/1652
- A61K9/1676
- A61P3/00
- A61P3/06
- A61P7/00
- A61P7/02
- A61P9/00
- IPC, 15
- A61K31 216
- A61K9 16
- A61K9 14
- A61K
- A61K9 10
- A61K9 48
- A61K9 64
- A61K47 02
- A61K47 20
- A61K47 30
- A61K47 38
- A61P3 00
- A61P3 06
- A61P7 02
- A61P9 00
Designated states25
- Contracting states, 19
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Extension states, 6
- Albania
- Lithuania
- Latvia
- North Macedonia
- Romania
- Slovenia
